{"id":52186,"date":"2021-06-07T05:10:19","date_gmt":"2021-06-07T05:10:19","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=74623"},"modified":"2021-06-07T05:10:19","modified_gmt":"2021-06-07T05:10:19","slug":"nyxoah-better-sleep-trial-reaches-its-primary-endpoints","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/","title":{"rendered":"Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints"},"content":{"rendered":"<p align=\"right\"><strong>REGULATED INFORMATION\u00a0<\/strong><br \/>\n<strong>INSIDE INFORMATION<\/strong><\/p>\n<p align=\"center\"><strong>Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints<\/strong><\/p>\n<p align=\"justify\"><strong>Mont-Saint-Guibert, Belgium \u2013 7 June 2021, 7:00 am CET \/ 1:00 am ET \u2013 Nyxoah SA (Euronext Brussels: NYXH)<\/strong>\u00a0(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the BETTER SLEEP trial reached its primary safety and performance endpoints.<\/p>\n<p align=\"justify\">The BETTER SLEEP trial was designed to assess the long-term safety and performance of the Genio\u00ae bilateral hypoglossal nerve stimulation system (the \u201cGenio\u00ae system\u201d) in 42 adult OSA patients with and without Complete Concentric Collapse (CCC) of the soft palate.<\/p>\n<p align=\"justify\">Top-line results from the BETTER SLEEP study showed:<\/p>\n<ul type=\"square\">\n<li>\u00a0A statistically significant mean reduction in Apnea Hypopnea Index (AHI) from baseline to six months post implantation in the whole cohort (CCC and non-CCC patients)<\/li>\n<li>\u00a0A statistically significant mean reduction in AHI from baseline to six months post implantation in the CCC patient subgroup<\/li>\n<li>\u00a042.9% of the study population had CCC<\/li>\n<\/ul>\n<p align=\"justify\">The Company expects to announce additional data with respect to the study as further analyses are conducted.<\/p>\n<p align=\"justify\">Dr. Richard Lewis, MBBS, FRACS, Principal Investigator of the BETTER SLEEP study, from Royal Perth Hospital and the University of Western Australia commented: \u201cThe top-line results of the BETTER SLEEP study are extremely encouraging. The most impressive aspect of the results is the responder rate of the CCC patient subgroup. These patients are excluded from unilateral hypoglossal nerve stimulation, but the BETTER SLEEP results showed a significant reduction in AHI in these patients following treatment with the Genio\u00ae system, which is the first device designed to deliver bilateral stimulation of the hypoglossal nerve. Overall, we have achieved a very high responder rate in both CCC and non-CCC patients, and the treatment with the Genio\u00ae system was well tolerated. We look forward to publishing this data in a leading medical journal.\u201d<\/p>\n<p align=\"justify\">Olivier Taelman, CEO of Nyxoah, stated: \u201cWe are excited by the top-line data, with the primary performance and safety endpoints met, supporting our belief that the Genio\u00ae system\u2019s bilateral stimulation of the hypoglossal nerve, has the potential to provide positive clinical outcomes for patients with CCC. We already engaged with the EU Notified Body to review these study data, with the goal of expanding the CE-marked indication to include CCC patients. In parallel, we plan to initiate dialogue with the FDA to further discuss the Genio\u00ae system as a potential treatment option for patients with CCC.\u201d Mr. Taelman continued, \u201cAdditionally, we observed a 70% responder rate in the non-CCC patient subgroup based on the Sher criteria, which strengthens our confidence in ongoing study outcomes.\u201d<\/p>\n<p align=\"justify\"><strong>About BETTER SLEEP Trial<\/strong><br \/>\nBilatEral Hypoglossal Nerve StimulaTion for TreatmEnt of ObstRuctive SLEEP Apnoea, or BETTER SLEEP, is a multicenter, prospective, open-label, two-group clinical trial, designed to assess the safety and performance of the Genio\u00ae system for the treatment\u00a0of OSA in adult patients with and without CCC. The BETTER SLEEP trial includes a subgroup of CCC patients who are currently contraindicated for unilateral hypoglossal nerve stimulation. The trial was authorized by the Australian and New Zealand regulatory authorities and is being conducted in nine local medical centers. The primary safety endpoint was the incidence of device-related serious adverse events six months post-implantation. The primary performance endpoint was the change in the AHI score from baseline to six months post-implantation measured by counting the number of events (apnea or hypopnea) that occur per hour collected during an overnight sleep study. Patients with moderate to severe AHI scores between 15 and 65 and aged between 21 and 75 years were eligible for enrollment if they failed, refused, or did not tolerate PAP treatment. Patients with a body mass index above 32 kg\/m\u00b2 were excluded.<\/p>\n<p align=\"justify\"><strong>About Nyxoah<\/strong><br \/>\nNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah\u2019s lead solution is the Genio\u00ae system, a CE-marked, patient-centered, minimally invasive, next generation hypoglossal neurostimulation therapy for treatment of moderate to severe OSA. OSA is the world\u2019s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.<\/p>\n<p align=\"justify\">Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio\u00ae system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for potential CE-mark indication expansion, the DREAM IDE pivotal study for potential FDA approval and the post-marketing EliSA study in Europe to evaluate the long-term safety and efficacy of the Genio\u00ae system.<\/p>\n<p align=\"justify\">For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cinfgXctSOHpkMHizVaIVQZD3y9C6ZUUxIeb-lNeKLkfj0Azv0TH0rBSIuLdelLlrVF5LRuZJ-5uxxByFA5pkQ==\"  rel=\"nofollow\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DcinfgXctSOHpkMHizVaIVQZD3y9C6ZUUxIeb-lNeKLkfj0Azv0TH0rBSIuLdelLlrVF5LRuZJ-5uxxByFA5pkQ%3D%3D&amp;source=gmail&amp;ust=1623131766373000&amp;usg=AFQjCNEw2BUSt82ASrOHTHUVrpfZlimREA\"><u>www.nyxoah.com<\/u><\/a>.<\/p>\n<p align=\"justify\"><strong>Caution<\/strong>\u00a0\u2013 CE marked since 2019. Investigational device in the United States. Limited by U.S. federal<br \/>\nlaw to investigational use in the United States.<\/p>\n<p align=\"justify\"><strong>Forward-Looking Statements<\/strong><br \/>\nThis press release includes certain disclosures that contain \u201cforward-looking statements,\u201d including, without limitation, statements regarding Nyxoah\u2019s expectations regarding the Genio\u00ae system; planned and ongoing clinical studies of the Genio\u00ae system; the potential advantages of the Genio\u00ae system; Nyxoah\u2019s goals with respect to the development, regulatory pathway and potential use of the Genio\u00ae system; and the utility of prior clinical data, including data from the BETTER SLEEP study, in potentially obtaining FDA approval of the Genio\u00ae system. Forward-looking statements are based on Nyxoah\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ.\u00a0\u00a0Forward-looking statements contained in this announcement are made as of this date, and Nyxoah undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\"><strong>Contacts:<\/strong><br \/>\n<strong>Nyxoah<\/strong><br \/>\nFabian Suarez, Chief Financial Officer<br \/>\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CTLPhnbfcvpxWZhnuYVVekXJeoPs_GKTYLyeWgNKZ0Ylp5H06CBbm_Q-tNWCHJsC_3kExL1xASm_k3D4D0sv231qlRu4pKUbjE_wU6e6s5Y=\"  rel=\"nofollow\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DCTLPhnbfcvpxWZhnuYVVekXJeoPs_GKTYLyeWgNKZ0Ylp5H06CBbm_Q-tNWCHJsC_3kExL1xASm_k3D4D0sv231qlRu4pKUbjE_wU6e6s5Y%3D&amp;source=gmail&amp;ust=1623131766373000&amp;usg=AFQjCNG620nSAj-b9j8yLXP3ESTKo3WBvA\"><u>fabian.suarez@nyxoah.com<\/u><\/a><br \/>\n+32 10 22 23 55<\/p>\n<p align=\"justify\"><strong>Gilmartin Group<\/strong><br \/>\nVivian Cervantes<br \/>\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xJldVaKph1tH9LR41R6qf5UakixVYh8uv6HWNbLp4v1ONnTCh3RFQbTDF1YX2kBb4MgEShHYrPfb_T8q75SYZvsxwTKUkmhrz1kRD9Z0tER4X_dU9VTKpwsJz-jozSls\"  rel=\"nofollow\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DxJldVaKph1tH9LR41R6qf5UakixVYh8uv6HWNbLp4v1ONnTCh3RFQbTDF1YX2kBb4MgEShHYrPfb_T8q75SYZvsxwTKUkmhrz1kRD9Z0tER4X_dU9VTKpwsJz-jozSls&amp;source=gmail&amp;ust=1623131766373000&amp;usg=AFQjCNE7YiriI8PZgLaco6mZiI2mcQ_xbg\"><u>vivian.cervantes@gilmartinir.<wbr \/>com<\/u><\/a><\/p>\n<p id=\"m_3545659440971359545gnw_attachments_section-header\"><strong>Attachment<\/strong><\/p>\n<ul id=\"m_3545659440971359545gnw_attachments_section-items\">\n<li><a href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/4911dd0a-d0c6-456c-ac53-720d03578959\"  data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/4911dd0a-d0c6-456c-ac53-720d03578959&amp;source=gmail&amp;ust=1623131766373000&amp;usg=AFQjCNFvb4cVjbnk39ALZtI0xfLazuTbQQ\">ENG_Nyxoah &#8211; BETTER SLEEP Data PR &#8211; FINAL<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>REGULATED INFORMATION\u00a0 INSIDE INFORMATION Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints Mont-Saint-Guibert, Belgium \u2013 7 June 2021, 7:00 am CET \/ 1:00 am ET \u2013 Nyxoah SA (Euronext Brussels: NYXH)\u00a0(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[182,17,53,343],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints - Lebanon News Gazette<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints - Lebanon News Gazette\" \/>\n<meta property=\"og:description\" content=\"REGULATED INFORMATION\u00a0 INSIDE INFORMATION Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints Mont-Saint-Guibert, Belgium \u2013 7 June 2021, 7:00 am CET \/ 1:00 am ET \u2013 Nyxoah SA (Euronext Brussels: NYXH)\u00a0(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/\" \/>\n<meta property=\"og:site_name\" content=\"Lebanon News Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-07T05:10:19+00:00\" \/>\n<meta name=\"author\" content=\"lnadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"lnadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/\"},\"author\":{\"name\":\"lnadmin\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840\"},\"headline\":\"Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints\",\"datePublished\":\"2021-06-07T05:10:19+00:00\",\"dateModified\":\"2021-06-07T05:10:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/\"},\"wordCount\":953,\"publisher\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#organization\"},\"articleSection\":[\"Asean\",\"MENA\",\"Pakistan\",\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/\",\"url\":\"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/\",\"name\":\"Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints - Lebanon News Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#website\"},\"datePublished\":\"2021-06-07T05:10:19+00:00\",\"dateModified\":\"2021-06-07T05:10:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/lebanonnewsgazette.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#website\",\"url\":\"https:\/\/lebanonnewsgazette.com\/\",\"name\":\"Lebanon News Gazette\",\"description\":\"News from Lebanon\",\"publisher\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lebanonnewsgazette.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#organization\",\"name\":\"Lebanon News Gazette\",\"url\":\"https:\/\/lebanonnewsgazette.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png\",\"contentUrl\":\"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png\",\"width\":503,\"height\":261,\"caption\":\"Lebanon News Gazette\"},\"image\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840\",\"name\":\"lnadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"lnadmin\"},\"url\":\"https:\/\/lebanonnewsgazette.com\/author\/lnadmin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints - Lebanon News Gazette","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/","og_locale":"en_US","og_type":"article","og_title":"Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints - Lebanon News Gazette","og_description":"REGULATED INFORMATION\u00a0 INSIDE INFORMATION Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints Mont-Saint-Guibert, Belgium \u2013 7 June 2021, 7:00 am CET \/ 1:00 am ET \u2013 Nyxoah SA (Euronext Brussels: NYXH)\u00a0(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced [\u2026]","og_url":"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/","og_site_name":"Lebanon News Gazette","article_published_time":"2021-06-07T05:10:19+00:00","author":"lnadmin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"lnadmin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/#article","isPartOf":{"@id":"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/"},"author":{"name":"lnadmin","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840"},"headline":"Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints","datePublished":"2021-06-07T05:10:19+00:00","dateModified":"2021-06-07T05:10:19+00:00","mainEntityOfPage":{"@id":"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/"},"wordCount":953,"publisher":{"@id":"https:\/\/lebanonnewsgazette.com\/#organization"},"articleSection":["Asean","MENA","Pakistan","Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/","url":"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/","name":"Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints - Lebanon News Gazette","isPartOf":{"@id":"https:\/\/lebanonnewsgazette.com\/#website"},"datePublished":"2021-06-07T05:10:19+00:00","dateModified":"2021-06-07T05:10:19+00:00","breadcrumb":{"@id":"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/lebanonnewsgazette.com\/nyxoah-better-sleep-trial-reaches-its-primary-endpoints\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lebanonnewsgazette.com\/"},{"@type":"ListItem","position":2,"name":"Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints"}]},{"@type":"WebSite","@id":"https:\/\/lebanonnewsgazette.com\/#website","url":"https:\/\/lebanonnewsgazette.com\/","name":"Lebanon News Gazette","description":"News from Lebanon","publisher":{"@id":"https:\/\/lebanonnewsgazette.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lebanonnewsgazette.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lebanonnewsgazette.com\/#organization","name":"Lebanon News Gazette","url":"https:\/\/lebanonnewsgazette.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/","url":"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png","contentUrl":"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png","width":503,"height":261,"caption":"Lebanon News Gazette"},"image":{"@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840","name":"lnadmin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"lnadmin"},"url":"https:\/\/lebanonnewsgazette.com\/author\/lnadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/posts\/52186"}],"collection":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/comments?post=52186"}],"version-history":[{"count":0,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/posts\/52186\/revisions"}],"wp:attachment":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/media?parent=52186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/categories?post=52186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/tags?post=52186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}